Cadence Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Cadence Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-152,428	Closed	-$2.5M	–	473
2019 Q4	$2.5M	Sell	152,428 -20,084	-12%	-$304K	0.27%	83
2019 Q3	$2.29M	Sell	172,512 -6,690	-4%	-$93.2K	0.33%	111
2019 Q2	$2.52M	Sell	179,202 -5,984	-3%	-$95.2K	0.25%	117
2019 Q1	$3.41M	Buy	185,186 +65,508	+55%	+$1.49M	0.31%	79
2018 Q4	$3.13M	Sell	119,678 -55,575	-32%	-$1.31M	0.32%	76
2018 Q3	$4.02M	Buy	175,253 +29,234	+20%	+$597K	0.22%	111
2018 Q2	$2.78M	Buy	146,019 +42,433	+41%	+$710K	0.16%	142
2018 Q1	$1.75M	Sell	103,586 -5,488	-5%	-$91.9K	0.11%	238
2017 Q4	$1.66M	Buy	109,074 +46,468	+74%	+$690K	0.11%	255
2017 Q3	$1.12M	Buy	+62,606	New	+$1.05M	0.07%	366

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cadence Capital Management's VNDA Position: Q1 2020 in Review

Cadence Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2020, closing a stake of 152,428 shares — an estimated $2.5M sold.

Cadence Capital Management first reported a position in VNDA in Q3 2017 and held it in 10 quarters. The position peaked at $4.02M in Q3 2018. 159 funds tracked by Wall St. Rank hold VNDA as of Q1 2020.

Cadence Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Cadence Capital Management sold 152,428 Vanda Pharmaceuticals shares in Q1 2020, an estimated $2.5M.
Cadence Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2017 and held it in 10 quarters.
Cadence Capital Management's Vanda Pharmaceuticals position peaked at $4.02M in Q3 2018.
159 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2020.

Based on Cadence Capital Management's 13F filing for Q1 2020, filed 4 May 2020.